Table 1.
U.S. Food and Drug Administration–approved immune checkpoint inhibitors for cancer treatment.
| Name | Target | Indications | Approval date |
|---|---|---|---|
| Ipilimumab | CTLA-4 | Melanoma | Mar 2011 |
| Pembrolizumab | PD-1 | Melanoma | Sep 2014 |
| NSCLC | Oct 2015 | ||
| Head and neck cancer | Aug 2016 | ||
| Hodgkin lymphoma | Mar 2017 | ||
| MSI-H/dMMR | May 2017 | ||
| Bladder cancer | May 2017 | ||
| Gastric cancer | Sep 2017 | ||
| Cervical cancer | Jun 2018 | ||
| PMBCL | Jun 2018 | ||
| Hepatocellular carcinoma | Nov 2018 | ||
| Merkel cell carcinoma | Dec 2018 | ||
| Renal cell carcinoma | Apr 2019 | ||
| SCLC | Jun 2019 | ||
| Esophagus cancer | Jul 2019 | ||
| Endometrial carcinoma | Sep 2019 | ||
| Nivolumab | PD-1 | Melanoma | Dec 2014 |
| NSCLC | Mar 2015 | ||
| Renal cell carcinoma | Nov 2015 | ||
| Hodgkin lymphoma | May 2016 | ||
| Head and neck cancer | Nov 2016 | ||
| Bladder cancer | Feb 2017 | ||
| Colorectal cancer | Aug 2017 | ||
| Hepatocellular carcinoma | Sep 2017 | ||
| SCLC | Aug 2018 | ||
| Cemiplimab | PD-1 | SCC | Sep 2018 |
| Atezolizumab | PD-L1 | NSCLC | Oct 2016 |
| Bladder cancer | May 2016 | ||
| SCLC | Mar 2019 | ||
| Breast cancer | Mar 2019 | ||
| Durvalumab | PD-L1 | Bladder cancer | Feb 2016 |
| NSCLC | Feb 2018 | ||
| SCLC | Mar 2020 | ||
| Avelumab | PD-L1 | Merkel cell carcinoma | Mar 2017 |
| Renal cell carcinoma | May 2019 | ||
| Ipilimumab+nivolumab | CTLA-4+PD-1 | Melanoma | Oct 2015 |
| Renal cell carcinoma | Apr 2018 | ||
| Colorectal cancer | Jul 2018 | ||
| Hepatocellular carcinoma | Mar 2020 |
Data from U.S. Food and Drug Administration website (before March 2020). MSI-H, high levels of microsatellite; dMMR, deficient mismatch repair; PMBCL, primary mediastinal B-cell lymphoma; SCLC, small cell lung cancer; SCC, squamous cell carcinoma.